Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population

Adam J Savitz,1 Haiyan Xu,1 Srihari Gopal,1 Isaac Nuamah,1 Paulien Ravenstijn,2 David Hough,1 Ludger Hargarter3 1Janssen Research & Development, LLC, Raritan, NJ, USA; 2Janssen Research & Development, a Division of Janssen Pharmaceutica NV, Beerse, Belgium; 3Medical & Scient...

Full description

Bibliographic Details
Main Authors: Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Hargarter L
Format: Article
Language:English
Published: Dove Medical Press 2019-02-01
Series:Neuropsychiatric Disease and Treatment
Subjects:
long-acting injectable
non-inferiority
randomized
relapse
tolerability
Online Access:https://www.dovepress.com/efficacy-and-safety-of-paliperidone-palmitate-3-month-versus-1-month-f-peer-reviewed-article-NDT

Internet

https://www.dovepress.com/efficacy-and-safety-of-paliperidone-palmitate-3-month-versus-1-month-f-peer-reviewed-article-NDT

Similar Items